Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes

Latest Updates

News

Diasome Pharmaceuticals to Present HDV-Insulin Phase 2b Clinical Data at EASD 2026 and Inaugural Breakthrough T1D Clinical & Research Congress

Diasome Pharmaceuticals Strengthens Leadership Team as Company Prepares for Phase 3 Development

WKYC: "A smarter insulin, better meal timing and the avocado test"

CareTalk Podcast: "Targeting the Root Causes of Metabolic Disease w/ Bob Geho, Founder & CEO, Diasome”